Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRD Consolidation and Maintenance in Multiple Myeloma
NCT02253316Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2015
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in multiple myeloma (MM), sponsored by Washington University School of Medicine. Started Jan 2015; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02253316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253316.